CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.

ABSTRACT: Despite its established inter-individual variability, sildenafil has been the subject of only a few pharmacogenetic investigations, with limited data regarding the genetic modulators of its pharmacokinetics. We conducted a pharmacogenetic sub-study of patients randomized to sildenafil (n=85) in the RELAX trial, which investigated the impact of high-dose sildenafil in patients with heart failure with preserved left ventricular ejection fraction (HFpEF). In the overall population, the CYP3A4 inferred phenotype appeared associated with the dose-adjusted peak concentrations of sildenafil at week 12 and week 24 (adjusted P=0.045 for repeated measures analysis), although this P-value did not meet our corrected significance threshold of 0.0167. In the more homogeneous Caucasian subgroup, this ass

SUBMITTER: de Denus S 

PROVIDER: S-EPMC5656562 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature